Estimated Prevalence of Diabetes in the United States was reported on EndocrinologyAdvisor.com, 24 September, 2018 … and the numbers are staggering!
Guifeng Xu, M.D., from the University of Iowa in Iowa City, and colleagues conducted a nationwide study involving 58,186 adults aged 20 years or older to examine the prevalence of diagnosed diabetes, type 1 diabetes, and type 2 diabetes in the U.S. general population.
The researchers found that 6,317 adults received a diagnosis of diabetes. Among U.S. adults, the weighted prevalence of diagnosed diabetes, type 1 diabetes, and type 2 diabetes was 9.7, 0.5, and 8.5 percent, respectively.
Novo Nordisk, Flex expand their partnership beyond connected insulin pens was reported by Amirah Al Idrus on FierceBiotech.com, 24 October 2018.
Novo Nordisk has tapped Flex Digital Health’s internet-of-things platform to create new digital tools for people with diabetes. The duo previously teamed up on connected insulin pens, two of which are slated to launch early next year.
Their existing partnership focuses on building connectivity into devices, such as nonconnected insulin pens, so that patients and physicians can see exactly which insulin a patient takes, at what dose and when the patient administered it.
“We believe, at Flex and Novo Nordisk, that by making sure that data can be integrated into the smartphone, we can alleviate some of the burden on patients with diabetes,” said Anders Dyhr Toft, corporate vice president of Commercial Innovation at Novo Nordisk. The NovoPen 6 and NovoPen Echo Plus will launch in its first markets in early 2019, Toft said.
Read more: Novo Nordisk, Flex expand their partnership
Adding Metformin to T1D Therapy Reduces Insulin Dosages and Results in Weight Loss was published by Martin Hensel on InsulinNation.com, 26 October 2018. Wow, really, and we just thought Metformin was for T2s who were afraid of shots!
Metformin, an oral agent that works for hyperglycemia, is typically prescribed for type 2 diabetes patients to increase insulin sensitivity and activity. It is widely accepted for the treatment of type 2 diabetes and is frequently used off-label in Type 1 diabetes to limit insulin dose requirements. Recent studies further support that adding metformin to T1D insulin therapy can reduce average blood glucose levels and produce other desirable outcomes including weight reduction, controlled LDL-cholesterol levels, and reduced progression of atherosclerosis.
And more, Metformin May Improve Vascular Health in T1D Adolescents, also reported by Martin Hensel on InsulinNation.com, 2 November 2018.
The University of Colorado hypothesized that 1) T1D adolescents have impaired vascular function, and 2) metformin would improve their insulin resistance and vascular dysfunction. T1D adolescents demonstrate insulin resistance and impaired vascular health vs. controls. Metformin improves IR, regardless of baseline BMI, and BMI, weight, fat mass, insulin dose, aortic and carotid health in T1D adolescents. Metformin may hold promise as a cardioprotective intervention in T1D.
Race to introduce a T1D drug that inhibits glucose absorption was reported by Martin Hensel on InsulinNation.com, 25 October 2018. Lexicon and Boehringer Ingelheim/Lilly are completing Phase III trials that show great promise in reducing glucose absorption and lowering weight for people with T1D
Gliflozin drugs seem like they could meaningfully impact treatment results for both T1D and T2D. Most people will welcome the weight reduction benefits and the likely reduction in insulin requirements due to lower overall glucose levels also feels important.
Insulin discovery a game-changer for improving diabetes treatments was reported in Science Magazine, 4 November 2018.
Published in Nature Communications, the study reveals the first definitive 3D image of how insulin successfully interacts with its receptor – a ‘gatekeeper’ for transmitting information into cells – in a process that is crucial for instructing cells to lower blood sugar levels in the body. Understanding exactly what this process looks like could inform the design of faster-acting and longer-lasting insulin therapies.
How Machine Learning Fuels Diabetes Industry Solutions is a fabulous video of Bigfoot Biomedical Chief Engineer Lane Desborough in his presentation at the DiabetesMine DData Exchange 2018.